Xencor, Inc.

Stocks

Real-time Estimate Cboe BZX 05:58:34 27/10/26 am AEDT			5-day change	1st Jan Change
29.34 ^USD	+16.54%		+29.37%	+95.95%

04:57am	Top Midday Gainers	MT
02:38am	Wedbush Adjusts Price Target on Xencor to $45 From $30, Maintains Outperform Rating	MT

Published on 10/26/2026 at 11:50 pm AEDT - Modified on 10/27/2026 at 03:53 am AEDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Hello, and welcome to the Xencor ESMO 2026 webcast. [Operator Instructions] Also as a reminder, this conference call is being recorded today. If you

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

04:57am	Top Midday Gainers	MT
02:38am	Wedbush Adjusts Price Target on Xencor to $45 From $30, Maintains Outperform Rating	MT
11:50pm	Xencor, Inc. - Special Call
10:33pm	Top Premarket Gainers	MT
09:49pm	Xencor Shares Rise Pre-Bell After Kidney Cancer Trial Shows 45.5% Response Rate	MT
25/10	Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors	CI
26/09	Xencor's XmAb819 Data Could Support Registrational Path, Wedbush Says	MT
21/09	BofA Adjusts Price Target on Xencor to $26 From $20, Keeps Neutral Rating	MT
01/09	Raymond James Adjusts Xencor Price Target to $46 From $40, Maintains Strong Buy Rating	MT
06/08	Wedbush Adjusts Price Target on Xencor to $30 From $26, Maintains Outperform Rating	MT
06/08	RBC Capital Adjusts PT on Xencor to $20 From $19, Maintains Outperform Speculative Risk Rating	MT
06/08	Earnings Flash (XNCR) Xencor, Inc. Reports Q2 Revenue $51.2M, vs. FactSet Est of $18.9M	MT
06/08	Xencor, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
31/07	Xencor Shares Rise After Settlement Deal With Alexion	MT
18/07	Xencor's Cancer Drug Study Selected for Oral Presentation at ESMO; Shares Rise	MT

Duration

Period

Sector